The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Keryx Biopharmaceuticals

  • KERX
  • NASDAQ
  • Consumer Products
  • Latest 18.18
  • Currency US$
  • Change 0.29
  • Percent Change 1.621 %
  • Volume 1,150
  • Wed Aug 27, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 18.15
  • Previous Close 17.89
  • High 18.20
  • Low 17.73
  • Bidx3 18.00
  • Askx10 18.35
  • 52-week High08/27 18.20
  • 52-week Low08/30 8.48
  • Beta 4.202
  • Market Cap 1,652.74M
  • EPS -0.79
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $10,000,000
  • Earnings $-58,210,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $105,250,000
  • Current Ratio 9.56

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $160,320,000
  • Liabilities $16,410,000
  • Liabilities-to-Equity Ratio 0.11

Price Ratios

  • Price to Sales 165.27
  • Price to Book 11.48
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Aug 7 $-0.23 Nov 3 $-0.27
Surprises Aug 7 4.35% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Aug 28, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

Related Securities
Symbol Type Latest % Chg

Officers

  • Michael P. Tarnok Chairman of the Board of Direc
  • Ron Bentsur Chief Executive Officer and Di
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

750 LEXINGTON AVENUE
NEW YORK, NY

Phone: (212)-531-5965
Fax: (212)-5315961

ir@keryx.com
www.keryx.com

Ideas & Discussion

Live Discussion of KERX on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.